Dietary Omega-3 Fatty Acids Linked to Lower Risk of Having a First Clinical Diagnosis of Central Ner
Dietary Omega-3 Fatty Acids Linked to Lower Risk of Having a First Clinical Diagnosis of Central Ner/About-the-Society/News/Dietary-Omega-3-Fatty-Acids-Linked-to-Lower-Risk-o … read morePosted At: National MS Society
Tovaxin® (T cell vaccination) granted fast-track designation by FDA/About-the-Society/News/Tovaxin®-(T-cell-vaccination)-granted-fast-track-d … read morePosted At: National MS Society
Multiple sclerosis: Newly discovered signal mechanism causes T cells to turn pathogenicMultiple sclerosis is an autoimmune disease in which the body’s immune system attacks the patient’s own cells. In this case, modified T cells...
MS Research Highlights In 2014 That Offer New Leads In Stopping MS, Restoring Function Lost, And En/About-the-Society/News/MS-Research-Highlights-In-2014-That-Offer-New-Lead … read morePosted At: National MS Society
Society Announces Its Largest Walk MS Sponsorship from Novartis Pharmaceuticals/About-the-Society/News/Society-Announces-Largest-Walk-MS-Sponsorship-with … read morePosted At: National MS Society
- Next story An FDA Approved Generic Form of Copaxone® (Glatiramer Acetate) For Relapsing MS Called Glatopa™ Is L
- Previous story Researchers at Major MS Meeting Report Progress in Wellness and Symptom Management
Join Our Mailing List
- What side effects can result from interferon?
- Watching myelin patterns form: Evidence for sheath remodeling revealed by in vivo imaging
- What happens when women stop MS treatment during pregnancy?
- Brain-repairing protein may lead to new MS drugs
- Searching for targeted treatments for inflammatory diseases
- Multiple sclerosis: ‘Guardian molecule’ may lead to new treatment
- Government Shutdown’s Impact on People with MSPosted At: National MS Society
- What you should know about neurosarcoidosis
- Swedish Study Compares Ritiximab with Approved Therapies for Relapsing MSPosted At: National MS Society
- Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre studyPosted At: MS Journal